BHWM
TCRR

Beaird Harris Wealth Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Beaird Harris Wealth Management’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-61
Closed -$92 – 500
2023
Q1 		$92 Hold
61
– – ﹤0.01% 468
2022
Q4 		$61 Hold
61
– – ﹤0.01% 729
2022
Q3 		$0 Hold
61
– – ﹤0.01% 547
2022
Q2 		$0 Hold
61
– – ﹤0.01% 661
2022
Q1 		$0 Hold
61
– – ﹤0.01% 762
2021
Q4 		$0 Buy
+61
New +$381 ﹤0.01% 680

Beaird Harris Wealth Management's TCRR Position: Q2 2023 in Review

Beaird Harris Wealth Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 61 shares — an estimated $92 sold.

Beaird Harris Wealth Management first reported a position in TCRR in Q4 2021 and held it in 6 quarters. The position peaked at $92 in Q1 2023. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

  • Beaird Harris Wealth Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Beaird Harris Wealth Management sold 61 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $92.
  • Beaird Harris Wealth Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2021 and held it in 6 quarters.
  • Beaird Harris Wealth Management's TCR2 Therapeutics Inc. Common Stock position peaked at $92 in Q1 2023.
  • 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Beaird Harris Wealth Management's 13F filing for Q2 2023, filed 26 Jul 2023.